Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
March 18, 2024
|
2 min read
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
March 7, 2024
|
2 min read
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
Jan. 5, 2024
|
2 min read